74

4690897

PATENT ABSTRACTS

M E T H O D F O R T R A N S F O R M A T I O N O F

A N A E R O B I C M I C R O O R G A N I S M S

Charles H Squires, Donald L Heefner, Ronald Evans, Beatrice J Kopp, Michael J Yarus as- signed to Synergen Associates lnc

Method for transforming anaerobic micro- organisms. Anaerobic microorganisms are in- duced to form L-forms. Genetic material capable of inducing the desired phenotype is in- troduced into the L-forms, after which the L- forms may be caused to regenerate their cell wall. These methods are also useful for obtaining desired biological products. Additionally, shut- tle vectors capable of transforming both aerobic and anaerobic microorganisms are set forth.

4690898

DNA C O D I N G F O R A S I G N A L P E P T I D E A N D D N A C O N T A I N I N G

T H E S A M E

Kuni Yamane, Kazutaka Ohmura, Hisato Yamazaki, Teruaki Shiroza, Sakura mura, Niihari gun, Ibaragi ken, Japan assigned to Yamane Kunio; The Calpis Food Industry Co Ltd ]Daicel Chemical Industries Ltd ]Off Corn Starch Co Ltd

This invention relates to DNA consisting of a DNA base sequence coding for the signal pep- tide: See Patent for Chemical Structure PS and to DNA containing said DNA base sequence. The DNA base sequence coding for said signal pep- tide includes, for example; See Patent for Chemical Structure PS The desired products in cells can be secreted out of cells by the use of a vector containing DNA consisting of the DNA base sequence coding for said signal peptide.

4690905

M E T H O D F O R R E M O V A L O F H U M A N A N T I B O D I E S T O

N A T I V E D N A F R O M S E R U M

Betty A Diamond assigned to Albert Einstein College of Medicine of Yeshiva University a division of Yeshiva University

The invention relates to monoclonal anti- idiotypic antibodies to human anti-DNA anti- bodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspec- ted of having systemic lupus erythematosus, and as therapeutic reagents in methods to remove the anti-native DNA antibodies from the serum of patients with systemic lupus erythematosus.

4691009

H Y B R I D P R O T E I N S P R O D U C E D BY A N U L T R A H I G H

P R O K A R Y O T I C E X P R E S S I O N S Y S T E M

John L Palmer, Algis Anilionis assigned to Repligen Corporation

Hybrid useful proteins are prepared by a novel biological system comprising a prokaryotic host transformed with novel hybrid plasmids£3 +0 +62 -glucuronidase (BG) gene DNA and the desired protein gene DNA. Specifically ex- emplified are plasmids which comprise BG gene DNA and protein A DNA. + I E. coli + L K-12 derivative hosts transformed with plasmid pBG3-2 + 66 N express + 22 60% of the desired fusion protein having protein A-like biological activity. Other useful proteins can be expressed via the elegant highly efficient expression system of the subject invention. + RE

4692409

M E T H O D F O R P R O D U C I N G L - A S P A R T I C A C I D

Masahiko Kisumi, Saburo Komatsubara, Tomoyasu Taniguchi, Kobe, Japan assigned to Tanabe Seiyaku Co Ltd

A novel microorganism of the genus Escherichia containing a hybrid plasmid prepared by in- tegrating a plasmid with a deoxyribonucleic acid carrying the gene for aspartase which is obtained from a microorganism of the genus Escherichia. An industrially advantageous method for pro- ducing L-aspartic acid comprising contacting a culture of the novel microorganism, microbial cells collected from the culture or a processed material of the microbial cells with fumaric acid and ammonia to produce L-aspartic acid and then collecting L-aspartic acid thus produced is also disclosed.